KnowTheStock
Log inCreate free account

ALNYLAM PHARMACEUTICALS, INC.

ALNY
Nasdaq 100Pharmaceutical Preparations · Nasdaq
$254.07last close · market cap 35.07 Billion
Compare with…
60.9SCORE / 100
Our verdictHOLDStrong Growth and ImprovingQtr Ending 2026-09-30 · trend positive

Why Hold

Income statement and balance sheet are strong; cash flow is moderate.

Next earnings: 2026-10-29 (BMO), EPS Forecast: $1.46

What is strong
  • Revenue Growth is 56.17%
  • Operating Income Growth is 269.32%
  • Net Income Growth is 2136.86%
  • Earnings Per Share (EPS) Growth is 2306.25%
  • Net Margin is 52.85%
  • Current Asset to Current Liability Ratio is 2.48
  • Current Debt to Net Income Ratio is 0.0
  • Total Debt to Total Assets Ratio is 0.0
  • Cash from Operations Growth is 351.58%
  • Capital Expenditure is Low
  • Net Increase in Cash is Positive
What to watch
  • Debt Ratio is 0.55
  • Investment Risk is High

What changed

Score by quarter

Upgraded from Sell to Hold in the Sep 2026 quarter: 58.0 → 60.9 (+2.9). This quarter: +2.9.

203040506070Mar 2023Sep 2026

What the score is made of

Income statement61.5 +3.6
Balance sheet67.5 +0.4
Cash flow46.7 +5.1

Change vs previous quarter.

Key numbers · latest quarter

Revenue (TTM)5.01 Billion56.17 % growth
EPS19.252306.25 % growth
Profit margin52.85 %Profit per $1 of sales
P-E ratio—Not available
Market cap35.07 BillionShares × price
Debt-equity ratio—Not available
Dividend0.00Per share, annual
Next earnings2026-10-29BMO · EPS forecast $1.46
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.

About ALNYLAM PHARMACEUTICALS, INC.

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

CEO
John Maraganore
Employees
2,246
Sector
Professional, Scientific, and Technical Services
Exchange
Nasdaq
alnylam.com

Similar stocks

Loading…